- Home
- RARE
as 02-21-2025 4:00pm EST
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | NOVATO |
| Market Cap: | 4.2B | IPO Year: | 2014 |
| Target Price: | $93.13 | AVG Volume (30 days): | 634.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 15 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.29 | EPS Growth: | N/A |
| 52 Week Low/High: | $37.02 - $60.37 | Next Earning Date: | 02-13-2025 |
| Revenue: | $560,230,000 | Revenue Growth: | 29.01% |
| Revenue Growth (this year): | 19.26% | Revenue Growth (next year): | 36.92% |
Stock Insider Trading Activity of Ultragenyx Pharmaceutical Inc. (RARE)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| KAKKIS EMIL D | RARE | President & CEO | Dec 30 '24 | Sell | $42.23 | 11,727 | $495,231.21 | 2,183,985 | |
| KAKKIS EMIL D | RARE | President & CEO | Dec 9 '24 | Sell | $50.00 | 8,273 | $413,650.00 | 2,183,985 |
Latest Ultragenyx Pharmaceutical Inc. News
RARE Breaking Stock News: Dive into RARE Ticker-Specific Updates for Smart Investing
Simply Wall St.
a day ago
Exploring Three High Growth Tech Stocks in the United States
GlobeNewswire
3 days ago
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
4 days ago
Ultragenyx Pharmaceutical Eyes Aug. 18 FDA Approval for Sanfilippo Syndrome Gene Therapy Treatment
GlobeNewswire
4 days ago
Ultragenyx Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)
Simply Wall St.
7 days ago
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?
Thomson Reuters StreetEvents
8 days ago
Q4 2024 Ultragenyx Pharmaceutical Inc Earnings Call
Zacks
8 days ago
Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y
GuruFocus.com
8 days ago
Ultragenyx Pharmaceutical Inc (RARE) Q4 2024 Earnings Call Highlights: Strong Revenue Growth ...
Compare RARE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RARE Ultragenyx Pharmaceutical Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.